Transcatheter atrial septal defects and patent foramen ovale closure: Medicare utilization and reimbursements
Vidit Majmundar, Rohan Deo, Ajay Kumar Mishra, Peng-Yang Li, Marina Byer, Rhea Sancassani · 2025
Read Transcatheter atrial septal defects and patent foramen ovale closure: Medicare utilization and reimbursements by Vidit Majmundar, Rohan Deo, Ajay Kumar Mishra, Peng-Yang Li, Marina Byer, Rhea Sancassani (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12400339.txt.
Description
Vidit Majmundar and co-authors tracked Medicare use of catheter-based heart defect closures from 2013 to 2022 in a 2025 paper. Devices delivered through a vein can seal an atrial septal defect or a patent foramen ovale, holes between the heart's upper chambers. Regulators approved them for serious shunts, stroke-causing clots, and decompression sickness.
Using national Medicare billing data, the team counted procedures and payments, adjusting dollars for inflation. Annual procedure numbers rose 81 percent over the decade. Trends like these show how a once-novel device becomes routine care, and help planners judge whether use and payment are growing at a sensible pace.
Catalog record
| CREATOR | Vidit Majmundar, Rohan Deo, Ajay Kumar Mishra, Peng-Yang Li, Marina Byer, Rhea Sancassani |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |